A Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy

Rose Parisi, Hemali Shah, Neil H. Shear, Michael Ziv, Alina Markova, Roni P. Dodiuk-Gad

Research output: Contribution to journalReview articlepeer-review


The rapid evolution of anti-cancer therapy (including chemotherapy, targeted therapy, and immunotherapy) in recent years has led to a more favorable efficacy and safety profile for a growing cancer population, and the improvement of overall survival and reduction of morbidity for many cancers. Anti-cancer therapy improves outcomes for cancer patients; however, many classes of anti-cancer therapy have been implicated in the induction of bullous dermatologic adverse events (DAE), leading to reduced patient quality of life and in some cases discontinuation of life-prolonging or palliative therapy. Timely and effective management of adverse events is critical for reducing treatment interruptions and preserving an anti-tumor effect. Bullous DAE may be limited to the skin or have systemic involvement with greater risk of morbidity and mortality. We present the epidemiology, diagnosis, pathogenesis, and management of bullous DAE secondary to anti-cancer therapies to enable clinicians to optimize management for these patients.

Original languageEnglish
Article number323
Issue number2
StatePublished - 24 Jan 2023


  • anti-cancer therapy
  • bullous
  • chemotherapy
  • cutaneous adverse events
  • dermatologic adverse events
  • immune checkpoint inhibitors
  • immunotherapy
  • targeted therapy

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'A Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy'. Together they form a unique fingerprint.

Cite this